SCHEMBL5434854

SCHEMBL5434854

CCN(Cc1ccc(OCCN2CCOc3ccccc32)cc1)OC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TSHR P16473 4/20 0.42
PPARG P37231 2/20 0.40
PPARA Q07869 2/20 0.40
KMT2A Q03164 1/20 0.40
HTR1A P08908 1/20 0.39
SLC6A4 P31645 1/20 0.39
HPGD P15428 1/20 0.39
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
CYSLTR2 Q9NS75 1/20 0.38
CYSLTR1 Q9Y271 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5101224 0.76 PPARG (0.49) LMNAMAPTRXFP1TSHRPPARG
SCHEMBL5428241 0.76 HTR1A (0.42) LMNAMAPTRXFP1TSHRPPARG
SCHEMBL5428793 0.76 PPARA (0.52) LMNATSHRPPARGPPARAALDH1A1
SCHEMBL14265753 0.76 PPARG (0.69) PPARGPPARA
SCHEMBL5107356 0.76 PPARG (0.69) PPARGPPARA
SCHEMBL5112766 0.75 PPARG (0.49) LMNAMAPTRXFP1TSHRPPARG
SCHEMBL5107391 0.75 KMT2A (0.43) LMNAMAPTRXFP1TSHRKMT2A
SCHEMBL5820210 0.75 PPARG (0.49) LMNAMAPTRXFP1TSHRPPARG
SCHEMBL14360396 0.75 PPARA (0.44) LMNAMAPTRXFP1TSHRPPARG
SCHEMBL14360288 0.75 LTA4H (0.48) LMNAMAPTRXFP1TSHRPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 LMNA 949/4885MAPT 162/4885RXFP1 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.